Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
Syros Pharmaceuticals (NASDAQ:SYRS) has announced its participation in two upcoming events. At the Society of Hematologic Oncology (SOHO) Annual Meeting from September 4-7 in Houston, Texas, Syros will present additional data from the randomized portion of the SELECT-AML-1 Phase 2 clinical trial. The presentation, titled 'SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy', is scheduled for September 4, 2024, at 5:15-6:30 PM CT.
Additionally, Syros management will participate in the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 11:30 AM ET in New York City. A live webcast of this presentation will be available on the company's website, with an archived replay accessible for approximately 30 days afterward.
Syros Pharmaceuticals (NASDAQ:SYRS) ha annunciato la sua partecipazione a due eventi imminenti. Al Society of Hematologic Oncology (SOHO) Annual Meeting che si svolgerà dal 4 al 7 settembre a Houston, Texas, Syros presenterà dati aggiuntivi dalla parte randomizzata del SELECT-AML-1 Trial Clinico di Fase 2. La presentazione, intitolata 'SELECT-AML-1: Trial Randomizzato di Fase 2 Tamibarotene in Combinazione con Venetoclax e Azacitidina in Pazienti Adulti con AML Precedentemente Non Trattati e con Sovraespressione di RARA, Inidonei per la Terapia di Induzione Standard', è in programma per il 4 settembre 2024, dalle 17:15 alle 18:30 CT.
Inoltre, il management di Syros parteciperà al H.C. Wainwright 26th Annual Global Investment Conference il 9 settembre 2024, alle 11:30 AM ET a New York City. Una diretta streaming di questa presentazione sarà disponibile sul sito web dell'azienda, con una registrazione archiviata accessibile per circa 30 giorni dopo.
Syros Pharmaceuticals (NASDAQ:SYRS) ha anunciado su participación en dos eventos venideros. En la Society of Hematologic Oncology (SOHO) Annual Meeting que se llevará a cabo del 4 al 7 de septiembre en Houston, Texas, Syros presentará datos adicionales de la parte aleatoria del SELECT-AML-1 ensayo clínico de Fase 2. La presentación, titulada 'SELECT-AML-1: Ensayo Aleatorizado de Fase 2 de Tamibarotene en Combinación con Venetoclax y Azacitidina en Pacientes Adultos con AML No Tratados Anteriormente y con Sobreexpresión de RARA, que No Son Elegibles para la Terapia de Inducción Estándar', está programada para el 4 de septiembre de 2024, de 5:15 a 6:30 PM CT.
Además, la dirección de Syros participará en la H.C. Wainwright 26th Annual Global Investment Conference el 9 de septiembre de 2024, a las 11:30 AM ET en la ciudad de Nueva York. Una transmisión en vivo de esta presentación estará disponible en el sitio web de la empresa, con una repetición archivada accesible durante aproximadamente 30 días después.
Syros Pharmaceuticals (NASDAQ:SYRS)는 두 개의 다가오는 이벤트에 참가할 것이라고 발표했습니다. Society of Hematologic Oncology (SOHO) Annual Meeting이 텍사스 휴스턴에서 9월 4일부터 7일까지 개최되며, Syros는 SELECT-AML-1 2상 임상 시험의 무작위 부분에서 추가 데이터를 발표할 예정입니다. 'SELECT-AML-1: 성인 이전 치료를 받지 않은 AML 환자와 RARA 과발현이 있는 환자에서 Venetoclax 및 Azacitidine과의 병용으로 Tamibarotene의 2상 무작위 시험'이라는 제목의 발표는 2024년 9월 4일, 오후 5:15-6:30 CT에 예정되어 있습니다.
또한, Syros 경영진은 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 2024년 9월 9일, 오전 11:30 ET에 뉴욕에서 참석할 예정입니다. 이 발표의 생중계는 회사 웹사이트에서 제공되며, 약 30일 후에 다시 볼 수 있는 아카이브 재방송도 제공될 것입니다.
Syros Pharmaceuticals (NASDAQ:SYRS) a annoncé sa participation à deux événements à venir. Lors de la Society of Hematologic Oncology (SOHO) Annual Meeting, qui se déroulera du 4 au 7 septembre à Houston, au Texas, Syros présentera des données supplémentaires provenant de la partie randomisée de l'essai clinique de phase 2 SELECT-AML-1. La présentation, intitulée 'SELECT-AML-1 : Essai Randomisé de Phase 2 de Tamibarotene en combinaison avec Venetoclax et Azacitidine chez des patients adultes atteints de LAM non traitée auparavant avec surexpression de RARA, inéligibles à la thérapie d'induction standard', est prévue pour le 4 septembre 2024, de 17h15 à 18h30 CT.
De plus, la direction de Syros participera à la H.C. Wainwright 26th Annual Global Investment Conference le 9 septembre 2024, à 11h30 ET à New York. Une diffusion en direct de cette présentation sera disponible sur le site Web de l'entreprise, avec une rediffusion archivée accessible pendant environ 30 jours après.
Syros Pharmaceuticals (NASDAQ:SYRS) hat seine Teilnahme an zwei bevorstehenden Veranstaltungen bekannt gegeben. Auf dem Society of Hematologic Oncology (SOHO) Annual Meeting, das vom 4. bis 7. September in Houston, Texas, stattfindet, wird Syros zusätzliche Daten aus dem randomisierten Teil der SELECT-AML-1 Phase 2-Studie präsentieren. Die Präsentation mit dem Titel 'SELECT-AML-1: Phase 2 Randomisierte Studie zu Tamibarotene in Kombination mit Venetoclax und Azacitidin bei erwachsenen Patienten mit zuvor unbehandelter AML und RARA-Überexpression, die für die Standard-Induktionstherapie nicht geeignet sind' ist für den 4. September 2024, von 17:15 bis 18:30 Uhr CT geplant.
Zusätzlich wird das Management von Syros am H.C. Wainwright 26th Annual Global Investment Conference am 9. September 2024, um 11:30 Uhr ET in New York City teilnehmen. Eine Live-Übertragung dieser Präsentation wird auf der Website des Unternehmens verfügbar sein, mit einem archivierten Replay, das etwa 30 Tage lang zugänglich ist.
- None.
- None.
Details are as follows:
12th Annual Meeting of the Society of Hematologic Oncology (SOHO 2024)
Presentation Title: SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy
Session Date & Time: Wednesday, September 4, 2024, 5:15-6:30 PM CT (6:15-7:30 PM ET)
Location: George R. Brown Convention Center
Poster Number: AML-347
The poster will be available on the Publications and Abstracts section of the Syros website at www.syros.com following the session.
H.C. Wainwright 26th Annual Global Investment Conference
Presentation Date & Time: Monday, September 9, 2024, 11:30 AM ET
Location: Lotte New York Palace
A live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
About Syros Pharmaceuticals
Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARα agonist in frontline patients with higher-risk myelodysplastic syndrome with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827332437/en/
Syros
Karen Hunady
Director of Corporate Communications & Investor Relations
1-857-327-7321
khunady@syros.com
Investors
Amanda Isacoff
Precision AQ
212-362-1200
amanda.isacoff@precisionaq.com
Source: Syros Pharmaceuticals
FAQ
When and where will Syros Pharmaceuticals (SYRS) present data from the SELECT-AML-1 Phase 2 trial?
What is the focus of Syros Pharmaceuticals' (SYRS) presentation at the SOHO 2024 meeting?
When is Syros Pharmaceuticals (SYRS) scheduled to present at the H.C. Wainwright Global Investment Conference?
How can investors access Syros Pharmaceuticals' (SYRS) presentation at the H.C. Wainwright conference?
